Open AccessColesterol e ictus: papel de los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9
Author(s) -
Luis CastillaGuerra,
M.C. Fernández-Moreno,
M Rico
Publication year - 2017
Publication title -
neurología
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 36
eISSN - 1578-1968
pISSN - 0213-4853
DOI - 10.1016/j.nrl.2017.03.009
Subject(s) - medicine , alirocumab , pcsk9 , humanities , ldl receptor , cholesterol , total cholesterol , lipoprotein , philosophy , apolipoprotein a1
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the modulation of plasma levels of low density lipoprotein cholesterol (LDLC). PCSK9 binds to the LDL receptor (LDLR), disrupts its endocytic recycling itinerary and directs it to lysosomal degradation. Activation of PCSK9 can thus decrease the expression of LDLR in the liver and inhibit LDL uptake, which leads to hypercholesterolaemia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom